IMCR vs. LEGN, ELAN, CYTK, NUVL, GRFS, VKTX, AXSM, KRYS, TGTX, and OGN
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), TG Therapeutics (TGTX), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.
Immunocore vs.
Immunocore (NASDAQ:IMCR) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Immunocore has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.
In the previous week, Legend Biotech had 4 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for Legend Biotech and 2 mentions for Immunocore. Immunocore's average media sentiment score of 0.79 beat Legend Biotech's score of 0.57 indicating that Immunocore is being referred to more favorably in the media.
Legend Biotech received 19 more outperform votes than Immunocore when rated by MarketBeat users. However, 73.03% of users gave Immunocore an outperform vote while only 71.79% of users gave Legend Biotech an outperform vote.
Immunocore has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.
Immunocore currently has a consensus price target of $65.64, indicating a potential upside of 126.18%. Legend Biotech has a consensus price target of $80.62, indicating a potential upside of 146.83%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Legend Biotech is more favorable than Immunocore.
84.5% of Immunocore shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 9.1% of Immunocore shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Immunocore has a net margin of -15.87% compared to Legend Biotech's net margin of -66.92%. Immunocore's return on equity of -12.84% beat Legend Biotech's return on equity.
Summary
Immunocore beats Legend Biotech on 10 of the 17 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
This page (NASDAQ:IMCR) was last updated on 1/20/2025 by MarketBeat.com Staff
